

Supplemental File 1

MOOSE Guidelines for Meta-Analyses and Systematic Reviews of Observational Studies*

	Topic	Page number
Title	Identify the study as a meta-analysis (or systematic review)	
Abstract	Use the journal's structured format	
Introduction	Present:	
	The clinical problem	
	The hypothesis	
	A statement of objectives that includes the study population, the condition of interest, the exposure or intervention, and the outcome(s) considered	
Sources	Describe:	
	Qualifications of searchers (eg, librarians and investigators)	
	Search strategy, including time period included in the synthesis and keywords	
	Effort to include all available studies, including contact with authors	
	Databases and registries searched	
	Search software used, name and version, including special features used (e.g. explosion)	
	Use of hand searching (e.g. reference lists of obtained articles)	
	List of citations located and those excluded, including justification	
	Method of addressing articles published in languages other than English	
	Method of handling abstracts and unpublished studies	
	Description of any contact with authors	
Study Selection	Describe	
	Types of study designs considered	
	Relevance or appropriateness of studies gathered for assessing the hypothesis to be tested	
	Rationale for the selection and coding of data (eg, sound clinical principles or convenience)	
	Documentation of how data were classified and coded (eg, multiple raters, blinding, and inter-rater reliability)	
	Assessment of confounding (e.g. comparability of cases and controls in studies where appropriate)	
	Assessment of study quality, including blinding of quality assessors; stratification or regression on possible predictors of study results	
	Assessment of heterogeneity	
	Statistical methods (eg, complete description of fixed or random effects models, justification of whether the chosen models account for predictors of study results, dose-response models, or cumulative meta-analysis) in sufficient detail to be replicated	
Results	Present	
	A graph summarizing individual study estimates and the overall estimate	
	A table giving descriptive information for each included study	
	Results of sensitivity testing (eg, subgroup analysis)	
	Indication of statistical uncertainty of findings	
Discussion	Discuss	
	Strengths and weaknesses	
	Potential biases in the review process (eg, publication bias)	

	Assessment of quality of included studies	
	Consideration of alternative explanations for observed results	
	Generalization of the conclusions (ie, appropriate for the data presented and within the domain of the literature review)	
	Guidelines for future research	
	Disclosure of funding source	

*Modified from Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–12. Copyrighted © 2000, American Medical Association. All rights reserved.

Supplemental File 2

Non-Laboratory Data						
Author, Month Year	Data collected Country	Dates of collected data	Confirmed Case	Deaths	ICU	Mechanical Ventivation
Stephen A. Lauer, Mar 2020	China	Jan 4, 2020 - Feb 24, 2020	181			
Chaolin Huang, Jan 2020	China	Dec 16, 2019 - Jan 2, 2020	41	6	7	4
Wei-jié Guan, Feb 2020	China	Dec 11, 2019 - Jan 29, 2020	1099	15	55	67
Dahai Zhao, Mar 2020	China	Jan 23, 2020 - Feb 5, 2020	19	0	0	0
Barnaby Edward Young, Mar 2020	Sinagapore	Jan 23, 2020 - Feb 3, 2020	18	0	2	1
De Chang, Feb 2020	China	Jan 16, 2020 - Jan 29, 2020	13	0		
Dawei Wang, Feb 2020	China	Jan 1, 2020 - Jan 28, 2020	138	6	36	17
Yixiang Ng, Mar 2020	Sinagapore	Jan 2, 2020 - Feb 29, 2020	100	0	15	
Gianfranco Spiteri, Mar 2020	Europe	Jan 24, 2020- Feb 21, 2020	38	1	3	1
COVID-19 National Incident Room Surveillance Team, Mar 2020	Australia	7 Mar 2020	71	2		
Xiao-Wei Xu, Feb 2020	China	10 Jan, 2020 - 26 Jan 2020.	62	0	1	1
Kristina L. Bajema, Feb 2020	USA	Jan 2020	11	1	4	
Moran Ki, Feb 2020	South Korea	Jan 20, 2020	28			
Nanshan Chen, Jan 2020	China	Jan 1, 2020 - Jan 20, 2020	99	11	23	
Jin-jin Zhang, Feb 2020	China	Jan 16, 2020 - Feb 3, 2020	140			
Xiaobo Yang, Feb 2020	China	Dec 24, 2019 - Jan 26, 2020	52	32	52	37
Zhongliang Wang, Mar 2020	China	Jan 16, 2020-Jan 29, 2020	69	5		
Pingzheng Mo, Mar 2020	China	Jan 1, 2020- Feb,1 2020	155			36
Matt Arentz, Mar 2020	USA	Feb 20, 2020 - Mar 5, 2020	21	11	21	15
Chaomin Wu, Mar 2020	China	Dec 25, 2019 - Jan 26, 2020.	201	44	53	67
Fei Zhou, Mar 2020	China	Dec 29, 2019- Jan 31, 2020	191	54	50	58

Laboratory Data						
Author, Month Year	Data collected Country	Dates of collected data	Confirmed Case	Leukopenia	Lymphopenia	Thrombocytopenia
Chaolin Huang, Jan 2020	China	Dec 16, 2019 - Jan 2, 2020	59	40	26	
Wei-jié Guan, Feb 2020	China	Dec 11, 2019 - Jan 29, 2020	1099	330/978	731/879	315/869
Dahai Zhao, Mar 2020	China	Jan 23, 2020 - Feb 5, 2020	19	7 of 19	12 of 19	
Barnaby Edward Young, Mar 2020	Sinagapore	Jan 23, 2020 - Feb 3, 2020	18	4.6(1.7-6.3)	1.2(0.8-1.7)	159(116-217)
Dawei Wang, Feb 2020	China	Jan 1, 2020 - Jan 28, 2020	138	4.5(3.3-6.2)	0.8(0.6-1.1)	163(123-191)
Nanshan Chen, Jan 2020	China	Jan 1, 2020 - Jan 20, 2020	99	9	35	12
Zhongliang Wang, Mar 2020	China	Jan 16, 2020-Jan 29, 2020	69		28	
Pingzheng Mo, Mar 2020	China	Jan 1, 2020- Feb,1 2020	155	4.36(3.30-6.03)	0.90(0.66-1.11)	170(127-208)
Chaomin Wu, Mar 2020	China	Dec 25, 2019 - Jan 26, 2020.	201	46	126	
Fei Zhou, Mar 2020	China	Dec 29, 2019- Jan 31, 2020	191	32/191	77	13

* Blank space indicates missing data

Discharged or Recovery	Antibiotic	Antiviral	Steroids	IVIG	Oxygen	Continuous renal replacement therapy	Direct exposure with infected	Travel History to China
								77
28	41	38	9		41	3	442	193
64	637	393	204	144	454	9		
0	0	19						19
		5			1			18
13								12
47	138	124	62		106	2		
							76	24
							14	
22							10	16
	28	55	16	16			62	
							2	9
								3
31	70	75	19	27	75	9		
							140	
8	49	23	30	28	33	9	27	
18	66	66	10		43			
		45	79	14	102		37	
2								
	196	170	62	0	165		99	
137	181	41	57	46	41	10		

Median Hb	Elevated ALT	Elevated AST	CRP	Procalcitonin	LDH	Creatinine kinase	Creatinine	D-dimer
		15						
13.4(11.9-14.8)	158/741	168/757	481/793	35/633	277/675	90/657	12/752	260/560
	5 of 18	5 of 18	18 of 19		6 of 19	1 of 18		
13.5(11.7-17.2)			16.3(0.9-97.5)		512(285-796)			
	24(16-40)	31(24-51)		49(35.5)	261(182-403)	14(10-18)	72(60-87)	203(121-403)
12.9	28	35			75	13	3	36
	23	19	42/63		25/61			
	23(16-38)	32(24-48)			277(195-404)	93(60-139)	71(60-87)	191(123-358)
	43	59	166		194		9	44
12.80(11.9-14.0)	59/189				123/184	22/168	8/186	117/172

China Resident	Male	Female	Age	Fever	Cough	Dyspnea	Myalgia+Fatigue	Sputum production	Headache	Diarrhea	Nausea/Vomiting	Hemoptysis	Sore throat
84	108	69	44.5										
483	30	11	49	41	31	22	18	11	3	1		2	
	637	459	47	1081	745	205	583	370	150	42	55	10	153
	11	8	48	15	9		2		2	1			4
	9	9	47	13	15	2				3			11
1	10	3	34	12	6		3	2	3	1			
	75	63	56	136	82	43	96	37	9	14	19		
	60	40	42.5										
	25	13	42	20	14	2	9		6	1	1		2
	35	36	45	24	22	3	12		12	9	2		17
	35	27	41	48	50	2	32	35	21	3		2	
			20	11	11								
6	15	13	42										
49	67	32	55.5	82	81	31	11	0	8	2	1	0	5
	71	69	57	110	90	44	90	0	0	18	31	0	0
	35	17	59.7	51	40	33	25	0	3	0	2	0	0
	32	37	42	60	38	20	50	20	10	10			
	86	69	54	126	97	50	110	0	8	7	6	0	0
	11	10	70	11	11	17	0	0	0	0	0	0	0
	128	73	51	188	163	80	65	83	0	0	0	0	0
	119	72	56	180	151	0	73	44	0	9	7	0	0

T. Bilirubin	PT	aPTT	BUN	ESR
76/722				
9.8(8.4-14.1)	13.0(12.3-13.7)			
18		6	6	
				30/58
				25
10		19		

Nasal congestion/Rhinorrhea	Smoking	Diabetes	Hypertension	Cardiovascular disease	Cerebrovascular disease	Pulmonary disease	Chronic Liver disease	Malignancy	Other Comorbidities
	3	8	6	6		1	1	1	13
	158	81	165	27		12	23	10	271
			2				1		2
1									
9									
		14	43	20	7	4	4	10	6
2				1					1
10									
		1	5		1	1	7		1
0				40				1	
0	9	17	42	12	3	2	8	0	36
3	2	9	0	5	7	4	0	2	2
		7	25	8		4	1	4	
0	6	15	37	15	7	5	7	7	5
0		7	0	9	0	9	1	1	17
0		22	39	8	7	5	0	1	2
0	11	36	58	15	0	6	0	2	24

Abnormal CT chest	Bilateral Lungs affected	Ground Glass opacity	Pneumonia	ARDS	Septic Shock	Cardiac complications	Secondary Infection	Other complications
41	40		41	12		5	4	
840	505	550	972	37	12			10
19	15	17	19					
6	3							
	9	6						
	138			27	12	33		5
			4					
			2			2		
	52	52	61					
	74	14		17	4			33
134	121	121						
			0	35	0	12	8	50
69		69						
	143							
21	11	10		20	0	7	4	8
	191		201	84				
191	143	136	112	59	38	77	28	104

USA																															USA				
Dates	28-Feb	29-Feb	1-Mar	2-Mar	3-Mar	4-Mar	5-Mar	6-Mar	7-Mar	8-Mar	9-Mar	10-Mar	11-Mar	12-Mar	13-Mar	14-Mar	15-Mar	16-Mar	17-Mar	18-Mar	19-Mar	20-Mar	21-Mar	22-Mar	23-Mar	24-Mar	25-Mar	26-Mar	27-Mar	28-Mar	29-Mar	30-Mar	31-Mar	Dates	
New cases	2	8	6	24	20	31	68	45	140	116	65	376	322	382	516	544	767	1133	1788	1360	5886	5412	6,381	7,769	10,381	10,052	12,021	18,037	17,798	19,793	19,402	20,872	26,257	Dates	
New deaths	0	1	0	5	1	4	1	2	3	4	1	6	8	4	7	7	9	22	23	10	82	44	62	109	134	154	236	267	371	445	441	508	892	New cases	
Cumulative cases	60	68	74	98	118	149	217	262	402	518	583	959	1281	1663	2179	2723	3490	4623	6411	7771	13657	19069	25,450	33,219	43,600	53,652	65,673	83,710	101,508	121,301	140,703	161,575	187,832	New deaths	
Cumulative deaths	0	1	1	6	7	11	12	14	17	21	22	28	36	40	47	54	63	85	108	118	200	244	306	415	549	703	939	1,206	1,577	2,022	2,463	2,971	3,863	Cumulative cases	
Case-fatality ratio	0	1.47	1.35	6.12	5.93	7.38	5.53	5.34	4.23	4.05	3.77	2.92	2.86	2.41	2.16	1.98	1.81	1.84	1.68	1.52	1.46	1.28	1.20	1.25	1.26	1.31	1.43	1.44	1.55	1.67	1.75	1.84	2.06	Cumulative deaths	
China																															China				
Dates	28-Feb	29-Feb	1-Mar	2-Mar	3-Mar	4-Mar	5-Mar	6-Mar	7-Mar	8-Mar	9-Mar	10-Mar	11-Mar	12-Mar	13-Mar	14-Mar	15-Mar	16-Mar	17-Mar	18-Mar	19-Mar	20-Mar	21-Mar	22-Mar	23-Mar	24-Mar	25-Mar	26-Mar	27-Mar	28-Mar	29-Mar	30-Mar	31-Mar	Dates	
New cases	330	433	577	205	126	125	153	154	80	53	37	29	35	12	14	35	32	38	35	67	62	121	73	108	125	115	90	138	130	118	138	84	97	Dates	
New deaths	44	47	35	42	33	36	32	29	28	28	23	16	22	11	8	13	10	14	13	11	8	5	6	9	7	4	3	5	3	5	7	1	1	New cases	
Cumulative cases	78962	79395	79972	80177	80303	80428	80581	80735	80815	80868	80905	80934	80969	80981	80995	81030	81062	81100	81135	81202	81264	81385	81458	81566	81691	81806	81896	82,034	82,164	82,282	82,420	82,504	82,601	New deaths	
Cumulative deaths	2,791	2,838	2,873	2,915	2,948	2,984	3,016	3,045	3,073	3,101	3,124	3,140	3,162	3,173	3,181	3,194	3,204	3,218	3,231	3,242	3,250	3,255	3,261	3,267	3,276	3,283	3,287	3,293	3,298	3,301	3,306	3,313	3,314	Cumulative cases	
Case-fatality ratio	3.53	3.57	3.59	3.64	3.67	3.71	3.74	3.77	3.8	3.83	3.86	3.88	3.91	3.92	3.93	3.94	3.95	3.97	3.98	3.99	4	4	4.00	4.01	4.01	4.01	4.01	4.01	4.01	4.01	4.01	4.01	4.02	4.01	Cumulative deaths
Italy																															Italy				
Dates	28-Feb	29-Feb	1-Mar	2-Mar	3-Mar	4-Mar	5-Mar	6-Mar	7-Mar	8-Mar	9-Mar	10-Mar	11-Mar	12-Mar	13-Mar	14-Mar	15-Mar	16-Mar	17-Mar	18-Mar	19-Mar	20-Mar	21-Mar	22-Mar	23-Mar	24-Mar	25-Mar	26-Mar	27-Mar	28-Mar	29-Mar	30-Mar	31-Mar	Dates	
New cases	233	240	566	342	466	587	769	778	1,247	1,492	1,797	977	2,313	0	5,198	3,497	3,590	3,233	3,526	4,207	5,322	5,986	6,557	5,560	4,789	5,249	5,210	6,203	5,909	5,974	5,217	4,050	4,053	Dates	
New deaths	4	8	5	18	27	28	41	49	36	133	97	168	196	0	439	175	368	349	345	475	427	627	793	651	601	683	712	919	889	756	812	837	New cases		
Cumulative cases	888	1,128	1,694	2,036	2,502	3,089	3,858	4,636	5,883	7,375	9,172	10,149	12,462	12,462	17,660	21,157	24,747	27,980	31,506	35,713	41,035	47,021	53,578	59,138	63,927	69,176	74,386	80,589	86,498	92,472	97,689	101,739	105,792	New deaths	
Cumulative deaths	21	29	34	52	79	107	148	197	233	366	463	631	827	827	1,441	1,809	2,158	2,503	2,978	3,405	4,032	4,825	5,476	6,077	6,820	7,503	8,215	9,134	10,023	10,779	11,591	12,428	Cumulative cases		
Case-fatality ratio	2.36	2.57	2.01	2.55	3.16	3.46	3.84	4.25	3.96	4.96	5.05	6.22	6.64	6.64	7.17	6.81	7.31	7.71	7.94	8.34	8.3	8.57	9.01	9.26	9.51	9.86	10.09	10.19	10.56	10.84	11.03	11.39	11.75	Cumulative deaths	
Iran																															Iran				
Dates	28-Feb	29-Feb	1-Mar	2-Mar	3-Mar	4-Mar	5-Mar	6-Mar	7-Mar	8-Mar	9-Mar	10-Mar	11-Mar	12-Mar	13-Mar	14-Mar	15-Mar	16-Mar	17-Mar	18-Mar	19-Mar	20-Mar	21-Mar	22-Mar	23-Mar	24-Mar	25-Mar	26-Mar	27-Mar	28-Mar	29-Mar	30-Mar	31-Mar	Dates	
New cases	143	205	385	523	835	586	591	1,234	1,076	743	595	881	958	1,075	1,289	1,365	1,209	1,053	1,178	1,192	1,046	1,237	966	1,028	1,411	1,762	2,206	2,389	2,926	3,076	2,901	3,186	3,110	Dates	
New deaths	8	9	11	12	11	15	15	17	21	49	43	54	63	75	85	97	113	129	135	147	149	149	123	129	127	122	143	157	144	139	123	117	141	New cases	
Cumulative cases	388	593	978	1,501	2,336	2,922	3,513	4,747	5,823	6,566	7,161	8,042	9,000	10,075	11,364	12,729	13,938	14,991	16,169	17,361	18,407	19,644	20,610	21,638	23,049	24,811	27,017	29,406	32,332	35,408	38,309	41,495	44,605	New deaths	
Cumulative deaths	34	43	54	66	77	92	107	124	145	194	237	291	354	429	514	611	724	853	988	1,135	1,284	1,433	1,556	1,685	1,812	1,934	2,077	2,234	2,378	2,517	2,640	2,757	2,898	Cumulative cases	
Case-fatality ratio	8.76	7.25	5.52	4.4	3.3	3.15	3.05	2.61	2.49	2.95	3.31	3.62	3.93	4.26	4.52	4.8	5.19	5.69	6.11	6.54	6.98	7.29	7.55	7.79	7.86	7.79	7.69	7.60	7.35	7.11	6.89	6.64	6.50	Cumulative deaths	
Spain																															Spain				
Dates	28-Feb	29-Feb	1-Mar	2-Mar	3-Mar	4-Mar	5-Mar	6-Mar	7-Mar	8-Mar	9-Mar	10-Mar	11-Mar	12-Mar	13-Mar	14-Mar	15-Mar	16-Mar	17-Mar	18-Mar	19-Mar	20-Mar	21-Mar	22-Mar	23-Mar	24-Mar	25-Mar	26-Mar	27-Mar	28-Mar	29-Mar	30-Mar	31-Mar	Dates	
New cases	17	13	39	36	45	57	37	141	100	173	400	622	582	0	2,955	1,159	1,407	2,144	1,806	2,162	4,053	2,447	4,964	3,394	6,368	4,749	9,630	8,271	7,933	7,516	6,875	7,846	7,967	Dates	
New deaths	0	0	0	0	1	1	1	2	5	7	11	7	19	1	78	62	94	53	191	90	207	213	332	397	539	497	839	718	773	844	821	913	748	New cases	
Cumulative cases	32	45	84	120	165	222	259	400	500	673	1,073	1,695	2,277	2,277	5,232	6,391	7,798	9,942	11,748	13,910	17,963	20,410	25,374	28,768	35,136	39,885	49,515	57,786	65,719	73,235	80,110	87,956	95,923	New deaths	
Cumulative deaths	0	0	0	0	1	2	3	5	10	17	28	35	54	55	133	195	289	342	533	623	830	1,043	1,375	1,772	2,311	2,808	3,647	4,365	5,138	5,982	6,803	7,716	8,464	Cumulative cases	
Case-fatality ratio	0	0	0	0	0.61	0.9	1.16	1.25	2	2.53	2.61	2.06	2.37	2.42	2.54	3.05	3.71	3.44	4.54	4.48	4.62	5.11	5.42	6.16	6.58	7.04	7.37	7.55	7.82	8.17	8.49	8.77	8.82	Cumulative deaths	
Germany																															Germany				
Dates	28-Feb	29-Feb	1-Mar	2-Mar	3-Mar	4-Mar	5-Mar	6-Mar	7-Mar	8-Mar	9-Mar	10-Mar	11-Mar	12-Mar	13-Mar	14-Mar	15-Mar	16-Mar	17-Mar	18-Mar	19-Mar	20-Mar	21-Mar	22-Mar	23-Mar	24-Mar	25-Mar	26-Mar	27-Mar	28-Mar	29-Mar	30-Mar	31-Mar	Dates	
New cases	2	31	51	29	37	66	220	188	129	241	136	281	451	170	1,597	910	1,210	1,477	1,985	3,070	2,993	4,528	2,365	2,660	4,183	3,930	4,337	6,615	6,933	6,824	4,400	4,790	4,923	Dates	
New deaths	0	0	0	0	0	0	0	0	0	0	2	0	1	0	4	2	2	6	7	4	16	23	17	10	29	34	49	61	75	91	100	112	130	New cases	
Cumulative cases	48	79	130	159	196	262	482	670	799	1,040	1,176	1,457	1,908	2,078	3,675	4,585	5,795	7,272	9,257	12,327	15,320	19,848	22,213	24,873	29,056	32,986	37,323	43,938	50,871	57,695	62,095	66,885	71,808	New deaths	
Cumulative deaths	0	0	0	0	0	0	0	0	0	0	2	2	3	3	7	9	11	17	24	28	44	67	84	94	123	157	206	267	342	433	533	645	775	Cumulative cases	
Case-fatality ratio	0	0	0	0	0	0	0	0	0	0	0.17	0.14	0.16	0.14	0.19	0.2	0.19	0.23	0.26	0.23	0.29	0.34	0.38	0.38	0.42	0.48	0.55	0.61	0.67	0.75	0.86	0.96	1.08	Cumulative deaths	
South Korea																															South Korea				
Dates	28-Feb	29-Feb	1-Mar	2-Mar	3-Mar	4-Mar	5-Mar	6-Mar	7-Mar	8-Mar	9-Mar	10-Mar	11-Mar	12-Mar	13-Mar	14-Mar	15-Mar	16-Mar	17-Mar	18-Mar	19-Mar	20-Mar	21-Mar	22-Mar	23-Mar	24-Mar	25-Mar	26-Mar	27-Mar	28-Mar	29-Mar	30-Mar	31-Mar	Dates	
New cases	571	813	586	599	851	435	467	505	448	273	164	35	242	114	110	107	76	74	84	93	152	87	147	98	64	76	100	104	91	146	105	78	125	Dates	
New deaths	0	3	1	11	0	7	0	7	2	6	3	1	6	0	6	3	0	6	3	7	3	8	2	7	9	6	5	8	5	8	6	4	4	New cases	
Cumulative cases	2,337	3,150	3,736	4,335	5,186	5,621	6,088	6,593	7,041	7,314	7,478	7,513	7,755	7,869	7,979	8,086	8,162	8,236	8,320	8,413	8,565	8,799	8,897	8,961	9,037	9,137	9,241	9,332	9,478	9,583	9,661	9,786	New deaths		
Cumulative deaths	13	16	17	28	28	35	35	42	44	50	53	54	60	66	66	72	75	75	81	84	91	94	102</												

Supplemental file 4

Global burden, epidemiology, outcomes, and interventions of COVID-19 pandemic- a systematic review

eFigure 1: Flow diagram of literature search and selection process of COVID-19

eFigure 2: Country-specific Case Fatality Rate (CFR)


eFigure 3: COVID-19 Specific death rate

eFigure 3A: COVID-19 Specific death rate (Cumulative-change)


eFigure 3B: COVID-19 Specific death rate (Daily-change)



eFigure 4: County-specific timeline of doubling time for cases and deaths



eFigure 1: Flow diagram of literature search and selection process of COVID-19




eFigure 4: County-specific timeline of doubling time for cases and deaths








INDIA



	30-Jan	4-Feb	9-Feb	14-Feb	19-Feb	24-Feb	29-Feb	5-Mar	10-Mar	15-Mar	20-Mar	25-Mar	30-Mar
New cases	1	1	2	23	13	11	50	103	29	227	146		
Cumulative cases	1	2	5	28	56	113	244	499	1,024	1,251	1,397		
Cumulative deaths	0	0	0	0	0	0	0	1	3	3	5		
New deaths	0	0	0	0	0	0	0	1	3	3	5		

SOUTH KOREA



	22-Jan	24-Jan	27-Jan	31-Jan	5-Feb	19-Feb	20-Feb	21-Feb	22-Feb	24-Feb	27-Feb	1-Mar	7-Mar	8-Mar	9-Mar	10-Mar	11-Mar	12-Mar	13-Mar	14-Mar	15-Mar	16-Mar	17-Mar	18-Mar	19-Mar	20-Mar	21-Mar	22-Mar	23-Mar	24-Mar	25-Mar	26-Mar	27-Mar	28-Mar	29-Mar	30-Mar	31-Mar
New cases	1	1	4	7	3	0	73	100	229	231	505	586	448	273	164	35	242	114	110	107	76	74	84	93	152	87	147	98	64	76	100	104	91	146	105	78	125
Cumulative cases	1	2	4	11	19	31	104	204	433	833	1,766	3,736	7,041	7,314	7,478	7,513	7,755	7,869	7,979	8,086	8,162	8,236	8,320	8,413	8,565	8,652	8,799	8,897	8,961	9,037	9,137	9,241	9,332	9,478	9,583	9,681	9,786
Cumulative deaths	0	0	0	0	0	0	1	2	2	8	13	17	44	50	53	54	60	66	66	72	75	75	81	84	91	94	102	104	111	120	126	131	139	144	152	158	162
New deaths	0	0	0	0	0	0	1	1	0	2	1	2	6	3	1	6	6	0	6	3	0	6	3	7	3	8	2	7	9	6	5	8	5	8	6	4	